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The The goal of this conference was to stimulate discussion between basic scientists and clinicians about the steps needed to move promising research related to SCI from laboratory animals into clinical trials. Marca Sipski, MD, first presented an overview of the issues associated with translational research in SCI. This was followed by a discussion of outcome measures in animal models with neurologic dysfunction by Timothy Schallert, PhD. Edelle Field-Fote, PhD, discussed the topic of measurement of motor function in animals and humans and the benefits of using motion analysis techniques. Christine Thomas, PhD, spoke about the measurement of motor function in humans versus animals. Alberto MartinezArizala, MD, discussed the measurement of sensory function in humans versus animals, providing insight into the benefits of using quantitative sensory testing. Mary Eaton, PhD, addressed animal models of pain and spasticity, and the morning ended with an update on neuroprotective techniques by John Bethea, PhD.
The afternoon session began with a discussion of neural regeneration by Mary Bunge, PhD. This was followed by a presentation on the ideal process for confirming that a therapy works in animals prior to transfer to humans by Dalton Dietrich, PhD. Jacqueline Sagen, PhD, next spoke about cellular therapies in SCI and what the Food and Drug Administration (FDA) will require to approve moving therapies from animals to humans, and Edward Hall, PhD, discussed drug development in SCI and working with the FDA. To round out the day, Irene Estores, MD, spoke about the consumer perspective-what
